Navigation Links
Simeprevir Administered Once Daily as Part of Combination Therapy Demonstrates Sustained Virologic Response in Treatment-Naive and Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
Date:11/2/2013

60;
In the pivotal Phase 3 PROMISE study, 79 percent of treatment-experienced hepatitis C patients treated with simeprevir in combination with pegylated interferon and ribavirin who previously experienced a relapse after prior treatment with pegylated interferon-based therapy achieved the primary endpoint of SVR12 compared to 37 percent of patients treated with placebo plus pegylated interferon and ribavirin. In this sub-analysis, 65 percent of patients with the IL28B TT genotype, 74 percent of patients with a METAVIR score of F4 and 70 percent of patients with genotype 1a HCV treated with simeprevir combined with pegylated interferon and ribavirin achieved SVR12 compared to 19 percent, 26 percent and 28 percent of patients taking placebo plus pegylated interferon and ribavirin, respectively. Among patients with the genotype 1a Q80K polymorphism at baseline, 47 percent of patients treated with simeprevir combined with pegylated interferon and ribavirin achieved SVR12 compared to 30 percent of patients treated with placebo in combination with pegylated interferon and ribavirin.

The most common adverse events in patients treated with simeprevir combined with pegylated interferon and ribavirin in the first 12 weeks were fatigue, headache and influenza-like illness. Three percent and 18 percent of patients treated with simeprevir combined with pegylated interferon and ribavirin experienced on-treatment failure and relapse, respectively, compared to 27 percent and 34 percent of patients taking placebo plus pegylated interferon and ribavirin, respectively.

"We are very proud of the depth and breadth of our clinical trial program," said Gaston Picchio, Disease Area Leader Hepatitis, Janssen Research & Development. "Following last week's positive vote from the FDA's Antiviral Drugs Advisory Committee to recommend approval of simeprevir, we look forward to making simeprevir available to patients living with chronic
'/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
2. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
3. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
4. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
5. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
6. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
7. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
8. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
9. MCOs Shifting Control Over Office-Administered Products from Medical to Pharmacy Benefit, Particularly Affecting Rheumatoid Arthritis Therapies
10. American Journal of Medicine Publishes Hypertension Study Comparing the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone versus Azilsartan Medoxomil Co-administered with Hydrochlorothiazide
11. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... , October 31, 2014 ... Corporation (NASDAQ: CELG ), Bristol-Myers Squibb Co. ... UNH ), Sanofi SA (NYSE: ... members receive these notes ahead of publication. To reserve ... . , ,-- ,Celgene Corporation Research Reports ,On October ...
(Date:10/31/2014)... , November 3, 2014 ... men with BPH to discuss "male orgasmic dysfunction" with ... ability to treat prostate symptoms while preserving sexual function ... welcomes the publication of a paper in the British ... from enlarged prostate to discuss with their doctors the ...
(Date:10/31/2014)... , Oct. 30, 2014 Migranade, Inc. announced ... be available to the 36 million U.S. migraine sufferers ... technology that targets the actual cause of migraines and ... pain and not the source Migranade is assured to ... MIGRANADE Migraine Relief is available at http://www.migranade.com ...
Breaking Medicine Technology:Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6Sexual Dysfunction No Longer Inevitable When Treating Enlarged Prostate 2Game Changing Migraine Medication To Be Available November 2014 2
... MYSTIC, Conn., Aug. 17 Amarin Corporation plc (Nasdaq: ... a focus on cardiovascular disease, today announced that Colin ... (CEO) and a member of the Company,s Board of ... responsible for driving forward the Company,s strategy to maximize ...
... - Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX ... care and gastroenterology markets, today announces financial results for the ... for full year 2010. Net Revenue:   ... was $10.7 million, up 9% from $9.8 million for the ...
Cached Medicine Technology:Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer 2Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer 3Amarin Corporation Appoints Colin W. Stewart as President and Chief Executive Officer 4Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 2Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 3Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 4Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 5Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 6Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 7Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 8Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 9Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 10Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 11Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 12Cumberland Pharmaceuticals Reports Second Quarter 2010 Financial Results 13
(Date:10/31/2014)... 31, 2014 Springboard Biodiesel, a ... small scale BioPro™ biodiesel processors, announced on Thursday ... improve the performance and efficiency of small-scale biodiesel ... trio will recover more than 99% of ... the glycerin by-product produced while making biodiesel. ...
(Date:10/31/2014)... The Memory Healer review published by DailyGossip.org reveals that the ... from Alzheimer's disease. , In fact, Alexander Lynch has ... His father pointed a gun and shot him during an ... of this method understood that he needed to do something ... is based on years of research. The author of the ...
(Date:10/31/2014)... At the start of 2014, numerous news ... monoxide poisoning in their homes. Now, as 2015 (and ... Missouri-based heating and cooling company is taking a more ... the home heating season with the assurance that their ... Nov. 1, 2014, E and Q Heating and Cooling ...
(Date:10/31/2014)... FRIDAY, Oct. 31, 2014 (HealthDay News) -- Surgery for ... on where in the United States you live, a ... will experience low back pain at some point in ... receive professional medical care for a spine problem," co-author ... & Clinical Practice, said in a college news release. ...
(Date:10/31/2014)... research suggests that insomnia is a major contributor to ... fatal injuries. The results underscore the importance of the ... Sleep Awareness Project. , Results show that the risk ... with the number of insomnia symptoms present. People with ... likely to die from a fatal injury than those ...
Breaking Medicine News(10 mins):Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 2Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 3Health News:"Memory Healer" Review Reveals a New Natural Remedy Guide for Managing Memory Loss 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2
... Reporter , TUESDAY, April 19 (HealthDay News) -- The first ... disease could double the number of Americans defined as having ... Alzheimer,s Association and the U.S. National Institute of Aging, differ ... been in use since 1984. First, Alzheimer,s is ...
... , TUESDAY, April 19 (HealthDay News) -- Minority ... more likely to die in early childhood than whites, a ... nearly 20,000 black, Hispanic and white infants born with congenital ... Overall, black infants were 32 percent more likely to die ...
... . FRANKFURT, Germany. It is a rare ... start experiencing vision impairments, which two to three years ... indication of a progressive destruction of brain cells. Later ... finally, failure of all motor abilities. In this last ...
... at the University of California, San Diego School of ... found in people may be useful as a future ... early and, in sufficient concentration, used as a treatment ... led by Richard Schwab, MD, assistant clinical professor of ...
... HealthDay Reporter , TUESDAY, April 19 (HealthDay News) -- About ... were going to get all of the recommended vaccinations, and ... immunizations, two new surveys find. Pediatricians and infectious disease ... about a supposed autism/MMR (measles, mumps, rubella) link -- ...
... 2011, Springer will publish Translational Behavioral Medicine: ... the Society of Behavioral Medicine. The journal will ... Evidence Implementation. Translational Behavioral Medicine ... online-first publication. Its aim is to engage, ...
Cached Medicine News:Health News: Alzheimer's Cases Could Double With New Guidelines: Expert 2Health News: Alzheimer's Cases Could Double With New Guidelines: Expert 3Health News:Minority Kids With Heart Defects More Likely to Die in Childhood 2Health News:Hope for children with rare genetic defect 2Health News:Hope for children with rare genetic defect 3Health News:A cancer marker and treatment in 1? 2Health News:A cancer marker and treatment in 1? 3Health News:Most Parents Vaccinate Kids, Trust Docs' Advice on Shots 2Health News:Most Parents Vaccinate Kids, Trust Docs' Advice on Shots 3Health News:Springer launches new journal, Translational Behavioral Medicine: Practice, Policy, Research 2
...
...
...
EDM Lumbar Drainage Kit with and without Bioglide are fabricated of radiopaque (barium impregnated) silicone tubing, and are packaged with stainless steel stylets inserted in the lumen....
Medicine Products: